164 related articles for article (PubMed ID: 29519711)
1. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis.
Tomasello G; Barni S; Turati L; Ghidini M; Pezzica E; Passalacqua R; Petrelli F
Clin Colorectal Cancer; 2018 Jun; 17(2):97-103. PubMed ID: 29519711
[TBL] [Abstract][Full Text] [Related]
2. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis.
Shigematsu Y; Inamura K; Yamamoto N; Mise Y; Saiura A; Ishikawa Y; Takahashi S; Kanda H
BMC Cancer; 2018 Oct; 18(1):980. PubMed ID: 30326864
[TBL] [Abstract][Full Text] [Related]
3. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CDX2 immunoexpression in poorly differentiated clusters of colorectal carcinoma.
Reggiani Bonetti L; Lionti S; Vitarelli E; Barresi V
Virchows Arch; 2017 Dec; 471(6):731-741. PubMed ID: 28819729
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.
Sandberg TP; Sweere I; van Pelt GW; Putter H; Vermeulen L; Kuppen PJ; Tollenaar RAEM; Mesker WE
Cell Oncol (Dordr); 2019 Jun; 42(3):397-403. PubMed ID: 30847807
[TBL] [Abstract][Full Text] [Related]
7. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
8. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract][Full Text] [Related]
9. Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancer.
Xu W; Zhu Y; Shen W; Ding W; Wu T; Guo Y; Chen X; Zhou M; Chen Y; Cui L; Du P
J Int Med Res; 2019 May; 47(5):1829-1842. PubMed ID: 30616445
[TBL] [Abstract][Full Text] [Related]
10. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
11. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
[TBL] [Abstract][Full Text] [Related]
12. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
13. High expression of anti-apoptotic protein Bcl-2 is a good prognostic factor in colorectal cancer: Result of a meta-analysis.
Huang Q; Li S; Cheng P; Deng M; He X; Wang Z; Yang CH; Zhao XY; Huang J
World J Gastroenterol; 2017 Jul; 23(27):5018-5033. PubMed ID: 28785155
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of abnormally expressed lncRNAs in colorectal cancer: A meta-analysis.
Wang J; Du S; Wang J; Fan W; Wang P; Zhang Z; Xu P; Tang S; Deng Q; Yang W; Yu M
PLoS One; 2017; 12(6):e0179670. PubMed ID: 28658310
[TBL] [Abstract][Full Text] [Related]
15. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
16. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
17. Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.
Wang L; Rambau PF; Kelemen LE; Anglesio MS; Leung S; Talhouk A; Köbel M
Histopathology; 2019 Feb; 74(3):452-462. PubMed ID: 30326146
[TBL] [Abstract][Full Text] [Related]
18. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer.
Nishiuchi A; Hisamori S; Sakaguchi M; Fukuyama K; Hoshino N; Itatani Y; Honma S; Maekawa H; Nishigori T; Tsunoda S; Obama K; Miyoshi H; Shimono Y; Taketo MM; Sakai Y
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31783700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]